Astera Labs, Inc. $ALAB Holdings Trimmed by Russell Investments Group Ltd.

Key Points

• Russell Investments Group Ltd. has reduced its stake in Astera Labs by 69.3%, selling 7,929 shares, and now holds 3,507 shares valued at approximately $209,000.
• Insider sales include COO Sanjay Gajendra selling 280,000 shares for over $47 million and CFO Michael Truett Tate selling 100,000 shares for around $17 million, reflecting significant declines in their respective positions.
• Astera Labs reported strong quarterly earnings, beating estimates with earnings per share of $0.44 and revenue growth of 149.5% year-over-year, with analysts setting varied price targets from $120 to $200.

Russell Investments Group Ltd. cut its holdings in shares of Astera Labs, Inc. (NASDAQ:ALAB - Free Report) by 69.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,507 shares of the company's stock after selling 7,929 shares during the period. Russell Investments Group Ltd.'s holdings in Astera Labs were worth $209,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Sound Income Strategies LLC raised its stake in shares of Astera Labs by 34.7% in the first quarter. Sound Income Strategies LLC now owns 792 shares of the company's stock worth $47,000 after buying an additional 204 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Astera Labs by 55.7% in the 1st quarter. GAMMA Investing LLC now owns 794 shares of the company's stock worth $47,000 after purchasing an additional 284 shares during the period. Harbour Investments Inc. boosted its holdings in Astera Labs by 351.7% during the 1st quarter. Harbour Investments Inc. now owns 795 shares of the company's stock valued at $47,000 after acquiring an additional 619 shares during the period. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Astera Labs during the 1st quarter valued at $48,000. Finally, Hazlett Burt & Watson Inc. lifted its holdings in shares of Astera Labs by 1,670.0% in the 1st quarter. Hazlett Burt & Watson Inc. now owns 885 shares of the company's stock worth $53,000 after buying an additional 835 shares during the period. Institutional investors own 60.47% of the company's stock.

Insiders Place Their Bets

In related news, CFO Michael Truett Tate sold 18,861 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $183.51, for a total value of $3,461,182.11. Following the completion of the sale, the chief financial officer directly owned 259,512 shares in the company, valued at approximately $47,623,047.12. This represents a 6.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jack R. Lazar sold 22,500 shares of the firm's stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $178.42, for a total value of $4,014,450.00. Following the sale, the director owned 97,351 shares of the company's stock, valued at $17,369,365.42. This represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,649,489 shares of company stock valued at $232,463,986. 12.50% of the stock is currently owned by company insiders.

Astera Labs Stock Performance

ALAB traded up $2.37 during trading on Wednesday, reaching $176.61. The company's stock had a trading volume of 3,126,453 shares, compared to its average volume of 5,376,900. Astera Labs, Inc. has a 52-week low of $36.85 and a 52-week high of $199.47. The company's fifty day moving average price is $137.83 and its 200-day moving average price is $97.51. The company has a market capitalization of $29.36 billion, a price-to-earnings ratio of 315.38, a price-to-earnings-growth ratio of 4.62 and a beta of 1.48.

Astera Labs (NASDAQ:ALAB - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.11. The firm had revenue of $191.93 million during the quarter, compared to analysts' expectations of $172.46 million. Astera Labs had a return on equity of 9.53% and a net margin of 16.54%.Astera Labs's revenue was up 149.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.13 earnings per share. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. Equities analysts predict that Astera Labs, Inc. will post 0.34 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Barclays reaffirmed an "overweight" rating and set a $155.00 target price (up from $75.00) on shares of Astera Labs in a research report on Thursday, August 7th. Evercore ISI increased their price target on Astera Labs from $104.00 to $215.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 6th. William Blair began coverage on Astera Labs in a report on Thursday, May 22nd. They issued an "outperform" rating for the company. CICC Research assumed coverage on Astera Labs in a research note on Friday, August 29th. They set an "outperform" rating and a $190.00 target price for the company. Finally, Wall Street Zen upgraded Astera Labs from a "hold" rating to a "buy" rating in a research report on Saturday, August 16th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, Astera Labs presently has a consensus rating of "Moderate Buy" and a consensus target price of $142.00.

About Astera Labs

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.